header-news

Latest News

New Supply Conditions Relating to Di-Gesic and Doloxene

January 8, 2014

On 1 January 2014 new conditions relating to the prescribing and dispensing of Di-Gesic (dextropropoxyphene HCl 32.5mg/paracetamol 325mg) and Doloxene (dextropropoxyphene napsylate) came into effect.

Read More >>

Di-Gesic Supply Update

November 19, 2013

Aspen Pharmacare Australia Pty Ltd wish to advise that Di-Gesic (dextropropoxyphene HCl 32.5mg/paracetamol 325mg)) stock has been released to wholesalers today.

Read More >>

Australian Packaging Covenant – Aspen Report 2013

October 30, 2013

The Australian Packaging Covenant is a voluntary initiative by Government and Industry to reduce the environmental effects of packaging. It is designed to minimise the environmental impacts arising from the disposal of used packaging, conserve resources through better design and production processes and facilitate the re-use and recycling of used packaging materials. Here you can view Aspen Australia's plan and report.

Read More >>

UPDATE in relation to Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate)

October 14, 2013

Please click on the 'Read full article' link below for an update on the current situation with Di-gesic and Doloxene.

Read More >>

Di-Gesic & Doloxene – Important information about interruption to product supply

October 4, 2013

Aspen Australia (Aspen) wishes to advise that it is unexpectedly out of stock of Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg).

Read More >>

Aspen 2013 Year-End Results

September 13, 2013

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2013.

Read More >>

ACQUISITION OF INFANT NUTRITIONAL (‘IN’) BUSINESSES FROM NESTLÉ

April 19, 2013

The Australian competition authorities have approved Aspen's acquisition of the Australian IN business and the transaction will be effective in Australia from 28 April 2013.

Read More >>

Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) to remain on ARTG

April 8, 2013

On 5th April, 2013 the Administrative Appeals Tribunal (AAT) decided that both Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) should remain on the Australian Register of Therapeutic Goods (ARTG), subject to the implementation of conditions to promote the safe use of these medicines.

Read More >>

Di-Gesic (dextropropoxyphene 32.5mg and paracetamol 325mg) and Doloxene (dextropropoxyphene napsylate100mg) – update 15 March 2013

March 26, 2013

Di-Gesic and Doloxene continue to be registered on the Australian Register of Therapeutic Goods (ARTG) and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.

Read More >>

Aspen To Continue Appeal Of TGA’s Decision

September 13, 2012

Aspen will continue to appeal the Therapeutic Goods Administration‟s decision to de-register Di-Gesic and Doloxene.

The TGA has affirmed its decision to cancel the registration of DPP products, however its decision will not take effect until further order of the AAT. Aspen remains concerned to ensure that patients are not left without adequate pain relief, and considers that this is likely to be the case if Di-Gesic and Doloxene are de-registered. Consequently, Aspen will continue its appeal.

Di-Gesic and Doloxene will remain on the register while Aspen‟s appeal is heard and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.

Read More >>